Clinical Trials Logo

Clinical Trial Summary

This study is being conducted to create a database for the Quotient® System iPad Test. Using community sampling, NCS Pearson will compile the results of this study to create a database against which the results of clinical Quotient tests may be compared to determine patient performance relative to the expected results for developmental age and gender.


Clinical Trial Description

Study Design:

This study is being conducted at 4 clinical sites and consists of up to two study visits. All study participants will complete at least one study visit. A smaller cohort of participants will complete a second visit for the purpose of assessing test retest reliability across the study sample. Subjects will be recruited using the clinic's relevant patient population and IRB approved recruitment material. Interested volunteers will participate in an initial screening, which may be done by telephone or in person that will be conducted by the clinic's research staff. Upon preliminary confirmation that the subject meets all inclusion criteria and does not meet any exclusion criteria, an appointment will be scheduled for the first study visit.

At the first visit, the study will be explained in detail. Adults will be asked to provide written informed consent. Parents or guardians of individuals under the age of 18 years old will provide written informed consent on behalf of the minor. Individuals between the age of 7 and 18 years of age will also provide their written assent. All consents and assents will be obtained prior to any study procedure being performed. Following consent, a brief medical history, including current medications the subject is taking, will be obtained. Subjects will complete a standard self-assessment questionnaire, appropriate for age, to screen for presence of ADHD. Subjects will not be excluded from the study based on responses to the questionnaire but their results will be considered in the analysis of study data. All subjects will take the appropriate version; Child (ages 6 -12.11), Adolescent (ages 13 - 19.11), or Adult (ages 20 - 79.11) of the 15-minute Quotient® System iPad Test.

At this visit, a cohort of participants across 7 age groups will be asked to return the clinic for a second study visit. These participants will be asked, in consecutive order of enrollment, to return to the clinic for a second study visit. Study participants who complete visit one are not required to participate in the retest cohort group and may opt out of returning to the clinic for visit two. Once the required number of participants (350 - 400) have completed the second study visit, that portion of the study will be closed to further enrollment and no further subjects will be given the option to return for the retest visit (visit 2).

Retest Visit 2 will occur 7 - 14 days following study visit 1. Subjects will be assessed for changes in health status and current medications since the time of visit 1. Subjects will repeat the appropriate version (Child, Adolescent or Adult) of the 15-minute Quotient® System iPad Test.

● Study Enrollment: A minimum of 1440 subjects with oversampling of 11%. Total enrollment is expected to be approximately 1600.

● Study Population:

Visit 1:

Male and female subjects from the age of 6 years until the age of 80 years. There will be a total of 16 age bands with approximately 90 subjects enrolled in each age band. Optimally, there will be a 50-50-male/female-gender stratification per each age category.

Visit 2:

A cohort of at least 350 subjects who have completed study Visit 1 will be asked to return for Visit 2. An oversampling of 11% is anticipated bringing the total number of subjects asked to return for Visit 2 to approximately 400. Visit 2 will include both male and female participants from 7 age bands.

- Study Procedures:

1. Review Inclusion/Exclusion Criteria

2. Obtain Written Adult Informed Consent

3. Obtain Written Minor Informed Assent

4. Verbal Report of Medical History

5. Concomitant Medications

6. Self-assessment Questionnaire:

1. ADHD Self Rating Scale (ADHDRS-IV) for subjects ages 6 - 19.11

2. ADHD Symptom Rating Scale (ASRS-V1.1) for subjects ages 20 - 79.11

7. Quotient® System iPad Test - Child, Adolescent or Adult test as appropriate for age

- Study Duration:

Dependent on accrual but estimated to be six (6) months to nine (9) months.

● Statistical Analysis Plan: The data of the study will be used to identify normative ranges and percentiles by age and gender. Each age range group of 90 will be compared for group differences between genders, and evaluated for the effects of age on performance. The SPSS software (SPSS Inc., Chicago, Illinois) will be used for statistic procedures in this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02693275
Study type Interventional
Source Pearson/Clinical Assessment
Contact
Status Completed
Phase N/A
Start date April 2016
Completion date March 31, 2017

See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1